Patient Stories|VPRIV® (velaglucerase alfa) for injection

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS

Make VPRIV your choice for patients during various stages of life.^1,2

Libby

Name: Libby
Age: 8
Age at type 1 Gaucher diagnosis: Newborn
Ethnicity: Ashkenazi Jewish
Treatment history: VPRIV, 3 years
Symptoms at baseline:
Enlarged spleen, low hemoglobin³
Last check-up:
Maintained improvements in spleen volume and hemoglobin count⁴

^*Not an actual patient. This is a hypothetical patient profile.

Libby’s parents discovered they were carriers of a type 1 Gaucher disease GBA gene mutation when they opted to do a carrier screening before they became pregnant with Libby.³

Libby underwent newborn screening and was diagnosed with type 1 Gaucher disease with the N370S mutation.⁵ She underwent routine monitoring every 6 months. Her doctors monitored her spleen and liver volumes, bone marrow infiltration, hemoglobin, and platelet counts.⁶ They also routinely took blood tests to monitor the following: glucosylsphingosine (lyso GL-1), chitotriosidase (CHIT1), chemokine ligand 18 (CCL-18), tartrate-resistant acid phosphatase (TRAP), and angiotensin-converting enzyme (ACE).^6,7

By age 5, Libby’s tests showed evidence for an enlarged spleen and abnormal platelet counts³ and her doctor recommended initiating ERT. After discussing the risks and benefits of therapy with her doctor, Libby’s parents selected VPRIV and Libby started receiving infusions before entering elementary school.

Consider

Type 1 Gaucher is a progressive, multi-systemic disease and routine monitoring is recommended.⁸

Looking to start your patients on VPRIV? Start the process by downloading a OnePath^® Start Form and filling it in with your patients to begin. Please contact OnePath^® at 1-866-888-0660 with any questions.

VPRIV OnePath® Start Form

Download the full VPRIV Patient Profiles here.

VPRIV Patient Profiles

VPRIV
Clinical Trials

Safety &
Tolerability Profile

Takeda Support Programs

STAY CONNECTED!

Fill in the required fields to stay up to date with news and announcements about VPRIV.

FIRST NAME*

LAST NAME*

EMAIL ADDRESS*

*By checking this box and clicking “Submit,” you certify that you are at least 18 years old, a US resident, and you are opting to receive information about VPRIV and other information from Takeda. You will be able to opt out of these communications using the unsubscribe feature.

Takeda respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Notice Statement. We encourage you to read our Privacy Notice Statement. This consent will be in effect until such a time as you opt out of the program.

FEEL EMPOWERED TO PRESCRIBE VPRIV AS A FIRST-LINE TREATMENT FOR YOUR TYPE 1 GAUCHER PATIENTS

Consider

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS